DJIA 17,356.87 288.00 1.69%
NASDAQ 4,644.31 96.48 2.12%
S&P 500 2,012.89 40.15 2.04%
market minute promo

22.54 2.08 (10.17%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

NBIX $22.54 10.17%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $20.45
Previous Close $20.46
Daily Range $20.19 - $22.56
52-Week Range $8.87 - $22.56
Market Cap $1.7B
P/E Ratio -28.42
Dividend (Yield) $0.00 (0.0%)
Volume 1,056,159
Average Daily Volume 664,435
Current FY EPS -$0.80





Neurocrine Biosciences, Inc. (NBIX) Description

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis. Website:

News & Commentary Rss Feed

Will These 3 Drugs Keep AbbVie's Future Bright After Humira?

While generic drugmakers will have a whale of a challenge creating a biosimilar of AbbVie's star drug Humira, this big pharma's thinking ahead with three up-and-coming drugs developing in its pipeline.

Auspex Drug Reduces Uncontrolled Movements in Huntington's Patients

Neurocrine Biosciences Reports Expansion of Clinical Pipeline

Neurocrine Biosciences Looking Forward To A Big Year

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q3 2014 Results - Earnings Call Transcript

KVB Capital LLC's Best And Worst Third-Quarter Performers

Neurocrine Initiates Tourette Syndrome Clinical Trial

Interesting NBIX Put And Call Options For May 2015

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman Presents at Morgan Stanley Healthcare Conference (Tr

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman Presents at Morgan Stanley Healthcare Conference (Transcript)

The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks

New Analyst Biotech Stocks to Buy With Gigantic Implied Upside

See More NBIX News...

NBIX's Top Competitors

NBIX $22.54 (10.17%)
Current stock: NBIX
AMGN $163.48 (2.53%)
Current stock: AMGN
GILD $102.40 (1.93%)
Current stock: GILD
BIIB $332.89 (2.39%)
Current stock: BIIB